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Abstract
Background: Acquisition of genital human papillomavirus (HPV) infection is common among the young, sexually active
population. Genital HPV infections do not always lead to seroconversion. We aimed to assess the association between
cervico-vaginal high risk (hr) HPV DNA and type-specific antibodies in an ethnically diverse cohort of young women.
Methods:Women of Dutch, South-Asian Surinamese, African Surinamese, Ghanaian, Moroccan and Turkish origin
participating in a large-scale multi-ethnic population-based cohort (the HELIUS study) provided vaginal self-samples and
blood samples, and completed a questionnaire regarding demographics, lifestyle and sexual health. Vaginal swabs were
tested for HPV using the highly sensitive SPF10-PCR DEIA/LiPA25 system (version1). Serum samples were tested for type-
specific L1 antibodies against 7 hrHPV types (16,18,31,33,45,52,58) with multiplex serology. We assessed the association
between vaginal HPV DNA and type-specific seropositivity with logistic and linear regression, using generalized estimating
equations (GEE). We determined whether this association varies by ethnicity by adding an interaction term.
Results: We selected 532 women who completed the questionnaire, provided a vaginal swab and a blood sample. Their
median age was 27 years (interquartile range 24–31 years). Prevalence of DNA of any of the 7 hrHPV was 22 %; HPV-52
was most common. Prevalence of antibodies against one or more hrHPV types was 24 %; HPV-16 seropositivity was most
common. In multivariable logistic regression analysis using GEE, adjusting for other determinants, vaginal HPV DNA
detection was associated with type-specific HPV seropositivity (OR 1.53, 95 % CI 1.06-2.20). In multivariable linear
regression analysis using GEE, the geometric mean of type-specific antibody reactivity was 1.15 (95 % CI 1.04-1.27) times
higher in women positive for HPV DNA compared to HPV DNA-negative women. There was little evidence that ethnicity
modified the association between HPV DNA, and type-specific seropositivity, or with antibody reactivities (p = 0.47 and
p = 0.57, respectively).
Conclusions: In this multi-ethnic group of young women in Amsterdam, cervico-vaginal hrHPV DNA detection was an
independent determinant of type-specific HPV seropositivity.
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Background
Due to increased globalization, European populations
are becoming more ethnically diverse, and health risks
and outcomes differ between ethnic groups [1]. Acquisi-
tion of human papillomavirus (HPV) infection is com-
mon among the young, sexually active population.
Oncogenic human papillomaviruses cause the majority
of cervical, anal, and penile cancer, and in some coun-
tries also of oropharyngeal cancer [2]. The incidence of
cervical carcinoma differs between ethnic groups in the
Netherlands, with higher incidence in those of the non-
Dutch origin [3].
Most infections with oncogenic HPV are cleared spon-
taneously and pass without malignant sequelae. Esti-
mates of proportions of women who seroconvert after
infection range from 55–85 %, depending on study de-
sign and methods employed [4–6]. The median time to
seroconversion after genital infection with HPV ranged
from 8.3–31.3 months between studies [4–6]. In a large
multi-national study 79 % of cases of cervical HPV DNA
cleared within 24 months [7]. Concordance of genital
HPV detection and serum antibodies is not expected per
se, because the former may constitute current infection,
and the latter past infection or infection of longer dur-
ation. Some studies, examining the concordance be-
tween cervico-vaginal HPV DNA and type-specific
seropositivity showed positive associations, while others
showed no significant relationship [8–15].
We aimed to assess the association between prevalent
cervico-vaginal HPV DNA of seven high risk HPV
(hrHPV) types and type-specific antibodies in serum, and
to evaluate whether this association varies by ethnicity.
Methods
Study design
The HEalthy LIfe in an Urban Setting (HELIUS) study is a
multi-ethnic cohort study conducted in Amsterdam which
has been described in detail elsewhere [16]. Briefly, the
study was initiated in 2011 and includes people aged 18–
70 years from the 6 largest ethnic groups in Amsterdam,
i.e. those of Dutch, South-Asian Surinamese, African
Surinamese, Ghanaian, Moroccan and Turkish origin.
Participants were randomly selected per ethnicity from
the Amsterdam municipal registers. Data were collected
by questionnaire and physical examination; collection of
biological samples took place during physical examination.
Information on demographic characteristics (age, educa-
tion, marital status), health-related characteristics (parity,
HPV vaccination, smoking), and sexual behavior (age at
sexual debut, number of lifetime male sex partners, type
of sexual partner in the preceding six months) were ob-
tained via questionnaire.
The selection process for this study has been described
in detail elsewhere (Alberts et al. 2015, manuscript
submitted for review). Briefly, we selected all women
aged 18–34 years from the HELIUS participants who
were enrolled until December 2013, who completed the
questionnaire on demographics, health behavioral char-
acteristics, and sexual behavior, provided a self-collected
vaginal swab, and of whom a blood sample was available
(n = 959). We randomly selected a maximum of 7
women per life year per ethnic group, resulting in a se-
lection of 610 women. Participants who were not tested
for HPV antibodies (n = 60), who reported HPV vaccin-
ation (n = 10) and participants with an invalid HPV
DNA test result (n = 8) were excluded, resulting in a
study sample of 532 women. The study protocol was ap-
proved by The Academic Medical Center Ethics Review
Board (Amsterdam, the Netherlands), and all partici-
pants provided written informed consent (reference
number METC 10/100# 17.10.1729).
HPV DNA detection and genotyping
Self-collected vaginal swabs (COPAN Italia, Brescia,
Italy) were stored at 4 °C for a maximum of 5–6 days at
the research location and sent to the Public Health Ser-
vice of Amsterdam where they were stored at −20 °C
until further analysis. Swabs were eluted in 600 μL PBS
and DNA was extracted from 200 μL of each specimen
using the isopropanol method [17] with an end volume
of 100 mL. The presence of HPV in the swabs was
assessed by using the highly sensitive SPF10-PCR DEIA/
LiPA25 system version 1 (DDL Diagnostics Laboratory,
Rijswijk, the Netherlands) [18]. Briefly, with this tech-
nique a 65 base-pair open reading frame of the L1 re-
gion was amplified with SPF10 primers resulting in
biotinylated amplicons. The amplification products were
tested for HPV DNA with a DNA enzyme immuno-
assay by use of hybridization with a cocktail of probes
that recognized at least 54 HPV types. Optical densities
were measured and compared with cut-off values from
internal controls. Positive samples were genotyped by a
reverse hybridization line probe assay which allows sim-
ultaneous detection of HPV-6, 11, 16, 18, 31, 33–35, 39,
40, 42–45, 51–54, 56, 58, 59, 66, 68/73, 70, and 74.
Prevalence of vaginal HPV DNA in this population and
determinants of vaginal HPV DNA detection have been
reported elsewhere (Alberts et al. 2015, manuscript sub-
mitted for review).
HPV antibody detection
Serum samples were stored at −80 °C at the Academic
Medical Center of Amsterdam until sent for analysis to
the German Cancer Research Center, Heidelberg,
Germany. Antibodies to the L1 proteins of HPV-16, 18,
31, 33, 45, 52 and 58 were analyzed by multiplex ser-
ology assay based on glutathione S-transferase (GST) fu-
sion protein capture on fluorescent beads (SeroMAP
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Table 1 Demographic, health and sexual behavior characteristics by ethnicity of 532 women from Amsterdam, the Netherlands
Dutch South-Asian Surinamese African Surinamese Ghanaian Moroccan Turkish Total
N = 98 N = 88 N = 100 N = 68 N = 101 N = 77 N = 532
n % n % n % n % n % n % P-value n %
Age in years
Median (IQR) 27 (23–31) 27 (23–31) 26 (22–30) 26 (21–30) 27 (23–30) 27 (23–31) 0.46 27 (23–30)
18–22 23 23 % 19 22 % 27 27 % 22 32 % 20 20 % 16 21 % 0.98 127 24 %
23–26 24 24 % 21 24 % 25 25 % 16 24 % 28 28 % 17 22 % 131 25 %
27–30 26 27 % 26 30 % 25 25 % 15 22 % 28 28 % 24 31 % 144 27 %
31–34 25 26 % 22 25 % 23 23 % 15 22 % 25 25 % 20 26 % 130 24 %
Educationa
Low/Intermediate 28 29 % 56 64 % 67 68 % 50 75 % 66 65 % 58 75 % <0.001 325 61 %
High 70 71 % 32 36 % 32 32 % 17 25 % 35 35 % 19 25 % 205 39 %
Marital status
Married/Cohabitating 30 31 % 29 33 % 13 13 % 14 21 % 39 39 % 36 47 % <0.001 161 30 %
Never married 68 69 % 54 61 % 86 86 % 53 78 % 52 51 % 35 45 % 348 65 %
Divorced 0 0 % 5 6 % 1 1 % 1 1 % 10 10 % 6 8 % 23 4 %
Smoking status
Never 47 48 % 61 69 % 63 64 % 66 97 % 81 80 % 36 47 % <0.001 354 67 %
Former 20 20 % 8 9 % 11 11 % 2 3 % 6 6 % 10 13 % 57 11 %
Current 31 32 % 19 22 % 25 25 % 0 0 % 14 14 % 31 40 % 120 23 %
Smoking in pack years
Never 47 48 % 61 69 % 63 64 % 66 97 % 81 80 % 36 47 % <0.001 354 67 %
< 2 pack years 24 25 % 14 16 % 22 22 % 1 1 % 9 9 % 13 17 % 83 16 %
> 2 pack years 26 27 % 13 15 % 14 14 % 1 1 % 11 11 % 27 36 % 92 17 %
Age of sexual debut in years
Median (IQR)b 16 (15–18) 18 (17–20) 17 (15–18) 18 (16–19) 19 (17–22) 20 (18–22) <0.001 18 (16–20)
Never had sex 5 5 % 14 16 % 8 8 % 18 28 % 33 33 % 15 20 % <0.001 93 18 %
≥ 21 9 9 % 12 14 % 3 3 % 9 14 % 29 29 % 26 34 % 88 17 %
19-20 8 8 % 16 19 % 17 17 % 5 8 % 12 12 % 16 21 % 74 14 %
18-17 27 28 % 29 34 % 27 27 % 19 30 % 13 13 % 14 18 % 129 25 %













Table 1 Demographic, health and sexual behavior characteristics by ethnicity of 532 women from Amsterdam, the Netherlands (Continued)
Number of lifetime male sexual partners
Median (IQR) 6 (3–11) 2 (1–4) 5 (2–8) 2 (0–4) 1 (0–1) 1 (1–2) <0.001 3 (1–7)
Nonec 5 5 % 14 16 % 9 9 % 18 28 % 34 34 % 16 21 % <0.001 96 18 %
1 8 8 % 27 31 % 6 6 % 11 17 % 44 44 % 38 50 % 134 26 %
2–5 33 34 % 34 40 % 42 42 % 25 39 % 15 15 % 12 16 % 161 31 %
6–10 25 26 % 9 10 % 26 26 % 8 13 % 4 4 % 9 12 % 81 15 %
≥ 11 27 28 % 2 2 % 16 16 % 2 3 % 3 3 % 1 1 % 51 10 %
Type of sexual contact past 6 months
Never had sex 5 5 % 14 16 % 8 8 % 18 28 % 33 33 % 15 20 % <0.001 93 18 %
No sex 17 17 % 14 16 % 11 11 % 9 14 % 16 16 % 11 14 % 78 15 %
With steady partner only 55 56 % 55 64 % 60 60 % 34 53 % 49 49 % 39 51 % 292 56 %
With casual partnerd 21 21 % 3 3 % 21 21 % 3 5 % 2 2 % 11 14 % 61 12 %
IQR, interquartile range
P-values of categorical variables are based on Chi-squared test and p of continuous variables are based on the Kruskal-Wallis test
Missing values for: education, n = 2; age sexual debut, n = 8; lifetime male sexual partners, n = 9; type of sexual partner past 6 months, n = 8; smoking status, n = 1; smoking in pack years, n = 3. a Education was
categorized as low or intermediate education if participant had (1) never been to school or had primary schooling only, (2) followed vocational schooling or lower secondary schooling, or (3) followed intermediate/
higher secondary education schooling; and was categorized as high education if participant had followed higher vocational schooling or university. bOf those women who reported ever having sex. cThis category
includes women who never had sex and those who exclusively had sexual contact with women, therefore this category has a different number than the category “Never had sex” in the variables “Age of sexual debut













Microspheres; Luminex) [19]. Antibody quantity was de-
termined as the median R-phycoerythrin fluorescence
intensity (MFI) from at least 100 beads of the same in-
ternal color. MFI values were dichotomized as antibody
positive or negative based on predetermined cut-off
values for each antibody by analyzing MFI values ob-
tained from Korean HPV DNA-negative self-reported
virgin females using an algorithm of the mean plus 5
SDs after exclusion of outliers [12]. This resulted in cut-
offs varying from 394–712 MFI.
Statistical analysis
Differences in baseline characteristics between ethnic
groups were assessed using the Pearson’s chi-squared or the
Kruskal-Wallis test as appropriate. The statistical analysis
was restricted to HPV types 16, 18, 31, 33, 45, 52 and 58.
First, we assessed type-specific HPV seropositivity on a
dichotomous scale among both HPV DNA positive
women and HPV DNA negative women per individual
HPV type by performing standard univariable logistic
analyses. As a woman can be infected with multiple
HPV types simultaneously we also analyzed data on all 7
HPV types with univariable and multivariable logistic re-
gression models using generalized estimating equations
(GEE). We used a binomial distribution and an ex-
changeable correlation structure with robust variance.
We then investigated the association between cervico-
vaginal HPV DNA and type-specific antibody reactivities
using linear regression. For this purpose, we transformed
antibody reactivities to their natural logarithm. We first
undertook standard univariable and multivariable linear
regression for individual HPV types. Next, we proceeded
with univariable and multivariable linear regression
using GEE. Because the mean and standard deviation of
antibody reactivities of the 7 hrHPV types differed, we
standardized the natural logarithm of antibody reactivity
levels by calculating Z-scores. We used a Gaussian dis-
tribution and an exchangeable correlation structure, with
robust variance. Because we included a log-transformed
outcome variable in the linear regression analysis, we
back-transformed the regression coefficients in order to
ease interpretation. As a result, the coefficients can be
interpreted as a multiplicative factor of the geometric
mean; in other words the geometric mean of an antibody
reactivity in women who are positive for cervico-vaginal
HPV DNA, is equal to that factor times the geometric
mean of women who are HPV DNA negative.
All multivariable models were adjusted for an a priori
defined set of variables, i.e. age, ethnicity, marital status,
smoking in pack years, and number of lifetime male sex-
ual partners. We included age as a continuous variable
using restricted cubic splines with 4 knots. All variables
other than age were included as categorical variables. No
backward selection was done.
Only one sexual risk variable could be included in the
model because of multicollinearity between these vari-
ables. Also, only smoking in pack years and not smoking
status was included in the models because of multicolli-
nearity. For all other variables multicollinearity did not
appear to be a concern.
As a last step we investigated whether the association
between HPV seropositivity and HPV DNA varied by
ethnicity. To do this we tested for interaction by adding
an interaction term to the multivariable model. Stata
Statistical Software release 13.1 (StataCorp, College Sta-
tion, TX, USA) was used for statistical analyses.
Results
A total of 532 women were included in the analyses
(Table 1). The average age of the participants did not
differ between ethnic groups (median 27 years, inter-
quartile range (IQR) 23–30 years). All other baseline
characteristics differed across ethnic groups; we found
significant differences in education, marital status, and
smoking. Furthermore, lifetime male sexual partners, age
of sexual debut and type of sexual contact in in the last
Table 2 Vaginal hrHPV DNA and type-specific seropositivitya, and association of vaginal hrHPV DNA with type-specific antibodiesb




Seropositive among DNA + n (%)d Seropositive among DNA - n (%)e Crude OR for seropositivity
(95 % CI)f
16 32 (6 %) 73 (14 %) 6 (19 %) 67 (13 %) 1.49 (0.59,3.76)
18 20 (4 %) 59 (11 %) 4 (20 %) 55 (11 %) 2.08 (0.67,6.44)
31 28 (5 %) 68 (13 %) 6 (21 %) 62 (12 %) 1.94 (0.76,4.98)
33 7 (1 %) 36 (7 %) 2 (29 %) 34 (6 %) 5.78 (1.08,30.88)
45 8 (2 %) 51 (10 %) 1 (13 %) 50 (10 %) 1.35 (0.16,11.23)
52 43 (8 %) 54 (10 %) 9 (21 %) 45 (9 %) 2.61 (1.18,5.97)
58 9 (2 %) 46 (9 %) 3 (33 %) 43 (8 %) 5.58 (1.35,23.10)
CI, confidence interval; hrHPV, high risk human papillomavirus; IQR, interquartile range; OR, odds ratio. a Among 532 women from a population-based cohort
(HELIUS), Amsterdam, the Netherlands. bUnivariable analysis conducted with logistic regression. c Cut-offs used in this study: 422 MFI for HPV-16, 394 for HPV-18,
712 for HPV-31, 515 for HPV-33, 368 for HPV-45, 547 for HPV-52, and 371 MFI for HPV-58. dAmong number of HPV DNA positive women in column 2. eAmong
number of HPV DNA negative women, i.e. the number cited in column 2 subtracted from 532. fMultivariable analysis was not undertaken because of
small numbers
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Table 3 Associations of risk factors and seropositivity for seven hrHPV typesa; logistic regression using GEE
Crude OR 95 % CI P-value Adjusted ORb 95 % CI P-value
Cervico-vaginal HPV DNA
No 1 0.002 1 0.02
Yes 1.70 (1.22,2.36) 1.53 (1.06,2.20)
Age in yearsc
19 2.76 (1.34,5.70) 4.33 (2.07,9.06)
24 1 0.02 1 <0.001
29 1.07 (0.58,1.99) 1.10 (0.60,2.05)
34 1.53 (0.73,3.20) 1.53 (0.72,3.24)
Ethnicityd
Dutch 1 <0.001 1 0.22
South-Asian Surinamese 0.63 (0.30,1.31) 1.39 (0.65,2.96)
African Surinamese 1.80 (0.99,3.26) 1.96 (1.08,3.55)
Ghanaian 0.74 (0.34,1.59) 1.11 (0.48,2.55)
Moroccan 0.43 (0.20,0.94) 1.30 (0.57,2.96)
Turkish 0.36 (0.14,0.88) 0.85 (0.34,2.15)
Marital statuse
Ever married/Cohabitating 1 0.002 1 0.06
Never married 2.22 (1.33,3.69) 1.72 (0.98,3.03)
Smoking status
Never smoked 1 0.50
Former smoker 1.42 (0.74,2.73)
Current smoker 1.22 (0.73,2.03)
Smoking in pack years
Never smoked 1 0.023 1 0.04
< 2 years 1.92 (1.14,3.22) 1.45 (0.84,2.50)
≥ 2 years 0.81 (0.43,1.52) 0.57 (0.30,1.09)
Age of sexual debut
Never had sex 1 <0.001
≥ 21 1.31 (0.44,3.89)
19-20 2.29 (0.82,6.38)
18-17 4.03 (1.65,9.85)
≤ 16 5.50 (2.30,13.17)
Lifetime male sexual partners
None 1 <0.001 1 <0.001
1 1.88 (0.73,4.85) 3.61 (1.37,9.49)
2–5 3.44 (1.43,8.27) 4.29 (1.72,10.74)
6–10 6.27 (2.54,15.49) 11.2 (4.13,30.33)
≥ 11 7.08 (2.74,18.32) 12.07 (4.09,35.57)
CI, confidence interval; GEE, generalized estimating equations; hrHPV, high risk human papillomavirus; OR, odds ratio. aAmong 532 women from the population-
based cohort HELIUS, Amsterdam, the Netherlands, 2011–2013. bMultivariable models adjusted for age in years, ethnicity, marital status, smoking in pack years,
number of lifetime male sexual partners. cFor analytic purposes age was modeled using restricted cubic splines with knots at the 5th, 35th, 65th and 95th
percentile. The ORs of four ages from the total analysis with five years in between have been chosen for display in the table. dEffect estimates per ethnicity of va-
ginal hrHPV DNA detection for seropositivity in ORs (95 % CI): Dutch 1.74 (0.99,3.09), South-Asian Surinamese 2.13 (0.72,6.33), African Surinamese 1.43 (0.82,2.45),
Ghanaian 0.93 (0.25,3.48), Moroccan 0.67 (0.13,3.51), Turkish 4.01 (1.44,11.12). eFor marital status, the small category of divorced women was added to the category
of married or cohabitating women to prevent instability of the model
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six months varied significantly by ethnicity. Most women
reported having one steady sexual partner in the preced-
ing six months.
Vaginal HPV DNA of at least one of the 7 hrHPV types
was detected in 115 (22 %) women of whom some had
multiple infections with different HPV types; DNA of
HPV-52 was detected most often (Table 2). Of the 532
women, 130 (24 %) were seropositive for at least one of
the 7 hrHPV types; HPV-16 had the highest seropreva-
lence (14 %). Among women positive for DNA of an indi-
vidual HPV type, seropositivity for the corresponding
HPV type ranged from 13–33 %. Among HPV DNA nega-
tive women, seropositivity ranged from 6–13 %.
For all 7 HPV types we found that HPV DNA positive
women were seropositive for the corresponding type
more often than HPV DNA negative women (indicated
by ORs > 1 for all), but this was only significant for
HPV-33, 52 and 58 (Table 2). In univariable logistic re-
gression analysis using GEE cervico-vaginal HPV DNA
detection was significantly associated with type-specific
seropositivity (OR 1.70, 95 % CI 1.22 – 2.36) (Table 3).
After adjustment for age, ethnicity, marital status, smok-
ing in pack years, and number of lifetime male sexual
partners the association remained positive and statisti-
cally significant (OR 1.53, 95 % CI 1.06 – 2.20).
The geometric mean of the antibody reactivities in
MFI was higher among women who were positive for
cervico-vaginal HPV DNA. This was the case for all 7
hrHPV types, though only significant for HPV-31, 52
and 58 (Table 4). When we adjusted for age, ethnicity,
marital status, smoking in pack years, and lifetime num-
ber of male sexual partners in multivariable linear re-
gression models, DNA detection of HPV-31 remained
significantly associated with a higher antibody reactivity
for this type. For all other HPV types the back-
transformed regression coefficient was >1, but the asso-
ciation was not significant.
Next, we investigated the association between cervico-
vaginal HPV DNA and standardized antibody reactivities
with linear regression analysis using GEE. In univariable
linear analysis with GEE women with prevalent cervico-
vaginal HPV DNA had higher type-specific antibody re-
activities than women without cervico-vaginal HPV
DNA (back-transformed regression coefficient 1.15
[95 % CI 1.04 – 1.27]) (Table 5). In the multivariable
analysis the back-transformed regression coefficient
remained unchanged (1.15 [95 % CI 1.04 – 1.27]). This
indicates that women with cervico-vaginal HPV DNA
have higher type-specific antibody reactivities than
women without cervico-vaginal HPV DNA, independent
of other determinants.
We examined whether the effect of HPV DNA on
seropositivity differed by ethnicity by adding an inter-
action term to the models. Neither in logistic, nor in lin-
ear regression analyses using GEE did we detect
significant effect modification (p = 0.47 and p = 0.57,
respectively).
Discussion
Our results show that in this multi-ethnic group of
young women in Amsterdam, cervico-vaginal HPV DNA
detection is an independent risk factor of type-specific
HPV seropositivity and that detection of cervico-vaginal
HPV DNA is associated with higher antibody reactivities
of type-specific antibodies.
Variables that describe sexual behavior directly or that
could be considered a proxy for sexual behavior were
strongly associated with higher type-specific HPV anti-
body reactivities and HPV seropositivity. The latter has
also been shown by several other studies [8, 20, 21].







in MFI among DNA
negative (95 % CI)
Geometric mean of
antibody reactivities
in MFI among DNA
positive (95 % CI)
Back-transformed
regression coefficientb
95 % CI P-value Back-transformed
regression coefficientb
95 % CI P-value
HPV-16 80 (70–90) 110 (72–167) 1.39 (0.83,2.31) 0.21 1.34 (0.82,2.17) 0.24
HPV-18 104 (95–112) 134 (83–216) 1.30 (0.84,2.00) 0.24 1.26 (0.81,1.93) 0.30
HPV-31 141 (126–157) 303 (203–455) 2.16 (1.34,3.48) <0.001 1.68 (1.03,2.72) 0.04
HPV-33 80 (73–88) 128 (40–411) 1.59 (0.70,3.61) 0.26 1.17 (0.53,2.57) 0.69
HPV-45 78 (71–85) 120 (51–280) 1.54 (0.73,3.23) 0.26 1.34 (0.66,2.70) 0.42
HPV-52 90 (81–100) 147 (99–218) 1.63 (1.13,2.36) 0.01 1.30 (0.91,1.87) 0.15
HPV-58 85 (79–92) 165 (72–376) 1.93 (1.05,3.55) 0.03 1.52 (0.84,2.75) 0.16
CI, confidence interval; MFI, median fluorescence intensity. aMultivariable models adjusted for age in years, ethnicity, marital status, smoking in pack years,
number of lifetime male sexual partners. For analytic purposes age was modeled using restricted cubic splines with knots at the 5th, 35th, 65th and 95th
percentile. bThe back-transformed regression coefficient for antibody reactivities is interpreted as being the factor by which the geometric mean of antibody
reactivities of vaginal HPV DNA positive women is higher in comparison to women who do not have vaginal HPV DNA. For example, women in whom vaginal
HPV-31 DNA was detected have a median antibody reactivity which is 2.16 times higher than the antibody reactivity of HPV-31 DNA negative women
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Table 5 Associations of antibody reactivities for seven hrHPVa; linear regression using GEEb
Back-transformed regression
coefficientc
95 % CI P-value Adjusted back-transformed
regression coefficientc
95 % CI P-value
Cervico-vaginal HPV DNA
No 1 0.005 1 0.007
Yes 1.15 (1.04,1.27) 1.15 (1.04,1.27)
Age in yearsd
19 1.47 (1.11,1.95) 1.54 (1.18,2.01)
24 1 0.58 1 0.013
29 1.17 (0.95,1.43) 1.10 (0.90,1.34)
34 1.15 (0.89,1.48) 1.08 (0.84,1.39)
Ethnicitye
Dutch 1 <0.001 1 <0.001
South-Asian Surinamese 1.09 (0.86,1.39) 1.45 (1.13,1.85)
African Surinamese 1.57 (1.25,1.98) 1.62 (1.29,2.03)
Ghanaian 1.14 (0.89,1.48) 1.39 (1.07,1.82)
Moroccan 0.76 (0.60,0.96) 1.13 (0.88,1.45)
Turkish 0.73 (0.57,0.93) 1.07 (0.82,1.40)
Marital statusf
Ever married/Cohabitating 1 <0.001 1 0.05
Never married 1.30 (1.11,1.51) 1.19 (1.00,1.43)
Smoking status
Never smoked 1 0.73
Former smoker 1.10 (0.86,1.40)
Current smoker 0.99 (0.83,1.19)
Smoking in pack years
Never smoked 1 0.13 1 0.09
< 2 years 1.18 (0.96,1.45) 1.01 (0.82,1.24)
≥ 2 years 0.91 (0.74,1.11) 0.81 (0.66,0.99)
Age of sexual debut in years
Never had sex 1 <0.001
≥ 21 1.15 (0.90,1.47)
19-20 1.36 (1.06,1.76)
18-17 1.65 (1.32,2.07)
≤ 16 1.94 (1.56,2.41)
Lifetime male sexual partners
None 1 <0.001 1 <0.001
1 1.23 (0.99,1.53) 1.52 (1.20,1.92)
2–5 1.60 (1.30,1.98) 1.66 (1.32,2.09)
6–10 1.88 (1.47,2.40) 2.14 (1.63,2.82)
≥ 11 2.35 (1.77,3.11) 2.85 (2.06,3.95)
CI, confidence interval; GEE, generalized estimating equations; hrHPV, high risk human papillomavirus. a Among 532 women from the population-based cohort HELIUS,
Amsterdam, the Netherlands, 2011–2013. bFor this analysis the antibody reactivity was transformed to its natural logarithm, and subsequently standardized by calculating
Z-scores. cThe back-transformed regression coefficient is interpreted as being the factor by which the standardized antibody reactivities of women are higher in
comparison to women in the reference category, which in this analysis is the HPV DNA negative group. d For analytic purposes age was modeled using restricted cubic
splines with knots at the 5th, 35th, 65th and 95th percentile. The back-transformed regression coefficients of four ages from the total analysis with five years in between
have been chosen for display in the table. e Effect estimates per ethnicity of vaginal hrHPV DNA detection for antibody reactivity in back-transformed regression coeffi-
cient (95 % CI): Dutch 1.19 (0.97,1.45), South-Asian Surinamese 1.21 (0.91,1.62), African Surinamese 0.98 (0.81,1.19), Ghanaian 0.99 (0.73,1.36), Moroccan 1.29 (1.00,1.66),
Turkish 1.26 (0.98,1.61). fFor marital status, the small category of divorced women was added to the category of married or cohabitating women to prevent instability of
the model. Multivariable models adjusted for age in years, ethnicity, marital status, smoking in pack years, number of lifetime male sexual partners
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Since antibody formation in response to natural infection
is a slow process that could extend to over a year, we ex-
pected in this young study population that concordance be-
tween cervico-vaginal DNA and antibodies would be low.
Our study population however had a significant positive as-
sociation even after adjustment for other well-known risk
factors. Our study population most likely represents
women who contracted their HPV infection relatively re-
cently. A small proportion of these infections will become
persistent and the majority will be cleared [22, 23].
With these results we aim to show that the interpret-
ation of HPV (sero-)prevalences may not be as straight-
forward as sometimes is depicted, i.e. even though there
is a significant positive correlation between HPV DNA
and HPV seropositive participants, being HPV DNA
positive does not imply that a person inevitably will be
or will become HPV seropositive, while being HPV sero-
negative does not necessarily mean an individual has
never been exposed. Concordance between HPV DNA
and seropositivity therefore has little clinical application
as a diagnostic tool. However it may be valuable in de-
scribing the natural history of HPV infection.
Because seropositivity to HPV is a measure of lifetime
exposure to HPV we expected that age would be associ-
ated with HPV seropositivity. In our sample we found a
significant positive association with age 19 and seroposi-
tivity relative to the reference age of 24 years, whereas
the odds for seropositivity seem to not vary much with
29 and 34 years. A similar trend has been reported
by Scherpenisse et al. (2012); seropositivity percentages
rise sharply in the early twenties, then stabilize and do
not vary much until 59 years of age [24].
Both significant and non-significant associations be-
tween cervical HPV DNA and type-specific seropositiv-
ity have previously been reported [8–15]. We found a
significant positive association in our sample between
cervico-vaginal HPV DNA and type-specific seropositiv-
ity expressed on a dichotomous scale, and further
strengthened this conclusion by confirming it in an ana-
lysis with the outcome measure on a continuous scale.
Our finding of a positive association between cervico-
vaginal HPV DNA and type-specific antibodies is in
agreement with several previous studies [9, 12–15]. We
complement and expand available knowledge on HPV
by including seven hrHPV types in our analysis, where
most previous studies included fewer types.
Some previous studies differ in methodology to ours
in several respects, in that they were conducted amongst
women at higher risk for HPV infections (more sexual
risk behavior or patients with cervical dysplasia or re-
cruitment in STI clinics) [9, 13, 14]. In other publica-
tions, type-specific positive associations have also been
found in young women that were recruited from popula-
tions not at high risk of HPV infection [12, 15].
The fact that we could only include women who pro-
vided a cervico-vaginal swab might have introduced
some selection bias into our study. Alberts et al. (2015)
have shown that women of Turkish and Moroccan ori-
gin from the same study population who declined to
provide a sample exhibited less sexual risk behavior
(Alberts et al., 2015, submitted for review). However, no
significant differences were observed between women
who did and did not provide a self-swab for the other
ethnicities suggesting limited bias for these groups. The
ethnic diversity of our sample, and the concurrent ana-
lysis of 7 hrHPV types are strengths of this study. Be-
cause seropositivity is a measure of lifetime exposure to
HPV and not necessarily the result of a current infec-
tion, an association between cervico-vaginal HPV DNA
and seropositivity can be difficult to interpret.
Conclusions
In conclusion, we observed a positive association be-
tween cervico-vaginal DNA detection and type-specific
seropositivity. Moreover, we demonstrated higher type-
specific antibody reactivities in women who are HPV
DNA positive compared to HPV DNA negative women
in a multi-ethnic urban population of young women.
These associations were independent of demographic
and behavioral factors. There was little evidence that
ethnicity constituted a significant effect modifier in our
population which suggests that effect modifiers other
than genetic variation are at play that result in differing
HPV infection outcomes in ethnic minorities.
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